LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2a inhibitor (HIF-2a), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data.
Belzutifan
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2a inhibitor (HIF-2a), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data. ### Output: Belzutifan